Cancer therapies save lives but can harm the heart. As survival improves, more patients experience cancer‑therapy‑related cardiac dysfunction (CTRCD) – a spectrum of myocardial injury, cardiomyopathy and heart failure (HF). Awareness across specialties is vital.
Congratulations @TeresaLpezFdez1 @CarloTocchetti @FarmakisD @MarcoMetra #medtwitter #cancersurvivor #cancer #oncology #CardioTwitter @ICOSociety @oncodaily @OncBrothers @OncoAlert @OncoDailyIO @PrimaryCareNHS What is CTRCD? CTRCD captures cardiac injury, ventricular dysfunction and symptomatic HF due to chemo, targeted agents, immunotherapies or radiation therapy. Symptomatic CTRCD means overt HF; it’s more common in (but not limited to) older patients with pre‑existing cardiovascular disease.